Publications by authors named "Changfu Cheng"

Claim this Profile
R
Ryanodine receptor () mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis.
Yang Wang, Yun Chen, Libin Zhang, Jian Xiong, Lele Xu, Changfu Cheng

Transl Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
LuAnn Sabounjian, Philip Graham, Lijun Wu, Virginia Braman, Changfu Cheng

Clin Pharmacol Drug Dev· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine.
Vinita Uttamsingh, Richard Gallegos, Julie F Liu, Scott L Harbeson, Gary W Bridson, Changfu Cheng

J Pharmacol Exp Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis.
Xiaonan Tang, Gary Bridson, Jing Ke, Lijun Wu, Halil Erol, Changfu Cheng

J Chromatogr B Analyt Technol Biomed Life Sci· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.
Changfu Cheng, Sunanda Vedananda, Lijun Wu, Scott Harbeson, Virginia Braman

J Mass Spectrom· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry.
Changfu Cheng, Richard Gallegos, Gary Bridson, Lijun Wu, Scott Harbeson

J Mass Spectrom· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy.
Virginia Braman, Philip Graham, Changfu Cheng, David Turnquist, Mark Harnett

Clin Pharmacol Drug Dev· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis